Purchase Order 75F40124P00240

Award Date 6/20/24
Potential Completion Date 9/14/24
Potential Value $84K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lakewood, CO 80215, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $19,039.96 firm fixed price purchase order to Terumo BCT Inc., a foreign-owned, for-profit manufacturer of medical devices and blood and cell technologies. The contract, which does not have a set-aside designation, was awarded on July 9, 2018 with a completion date of July 8, 2021. Terumo BCT Inc. provides a wide range of products and services to federal...
This federal contract award is to Terumo BCT, Inc., a manufacturer of medical devices and provider of services related to blood and cell technologies. The $260,000.00 firm fixed price purchase order was issued by the Department of Health and Human Services, National Institutes of Health Clinical Center. The contract provides Terumo BCT's blood bag systems, tubing sets, sterile tubing welders, cell washing equipment, preventative maintenance services, and other accessories used in apheresis, cell...
This is a $84,896.64 firm fixed-price purchase order awarded by the Veterans Integrated Service Network 9 of the U.S. Department of Veterans Affairs to Terumo BCT Inc., a foreign-owned manufacturer of medical devices and provider of blood and cell technology services. The contract is for the provision of Terumo apheresis systems, which are used in blood processing and cellular therapy applications. Terumo BCT is an established federal contractor, holding several Indefinite Delivery Vehicles...
This award to Terumo BCT, Inc. is a firm fixed-price purchase order from the Department of Health and Human Services National Institutes of Health Clinical Center. The contract has a potential value of $119,154.00 and is not set aside for any particular business category. Terumo BCT, Inc. is a manufacturer of medical devices and provider of services related to blood and cell technologies, including equipment, consumables, and maintenance support for blood collection, processing, storage, and...
This is a firm fixed-price purchase order awarded by the Defense Health Agency to Terumo BCT Inc., a foreign-owned, for-profit manufacturer of medical devices and blood and cell technology services. The contract is for the delivery of 180 Teruflex blood bag systems, at a ceiling value of $226,627.08, with a period of performance through September 15, 2025. This award was made on a sole-source basis, with no set-aside designation, under the authority of FAR 13.106-1(b)(1)(i) due to Terumo BCT...
This federal contract award, valued at $63,000, was issued by the National Institutes of Health (NIH) Clinical Center to Terumo BCT, Inc., a foreign-owned, for-profit manufacturer of medical devices and provider of blood and cell technology services. The contract is a firm fixed-price purchase order with a completion date of June 4, 2018. Terumo BCT, operating as the Terumo Bct, Inc. Division and doing business as Caridianbct, provides a wide range of specialized products and services to federal...
The Food and Drug Administration (FDA) awarded a $11,106,465 definitive contract to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract, which does not have a set-aside designation, is for the development of an optimized pathogen inactivation process for whole blood. This contract was awarded under a Broad Agency Announcement (BAA) solicitation by the FDA to advance regulatory science and innovation across various...
This is a $130,000 firm fixed-price purchase order contract awarded by the Office of the Chief Operating Officer, a civilian agency, to Terumo BCT Inc. (Terumo BCT) for the provision of sterile connecting devices to be used in the preparation of highly purified immunotherapy products. The contract has an ultimate completion date of July 28, 2016. Terumo BCT is a foreign-owned, for-profit manufacturer of medical devices and provider of blood and cell technology services. While this contract was...
This is a firm fixed-price purchase order awarded by the Bureau of Medicine and Surgery, a component of the U.S. Department of Defense, to Terumo BCT Inc., a foreign-owned, for-profit medical device manufacturer, for the supply of laboratory blood bank supplies. The contract has a ceiling value of $76,838.60 and a completion date of September 28, 2018. Terumo BCT Inc. is the prime contractor, and there is no indication of any major subcontractors. The contract is not set aside for any specific...
This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services National Institutes of Health Clinical Center to Terumo BCT, Inc., a foreign-owned, for-profit manufacturer of medical devices and blood management products and services. The contract, valued at $115,350.00, is for the provision of blood bag systems, tubing sets, sterile tubing welders, cell washing equipment, preventative maintenance services, and other accessories used in apheresis, cell...

The U.S. Food and Drug Administration (FDA) awarded a $84,250.00 purchase order to Terumo BCT Inc. for a "Brand Name or Equal" Terumo Blood and Cell Technologies (BCT), Mirasol Illuminator, Ultraviolet (UV)/Riboflavin Whole Blood Pathogen Reduction Device. This device will be used by the FDA's Center for Biologics Research and Review (CBER), Office of Blood Research and Review (OBRR) to treat whole blood with and without inoculation of model pathogens as a control for evaluating candidate pathogen reduction technologies. The contract has a completion date of September 14, 2024. This is an unrestricted contract, as no set-aside designation was used.

Generated 8/16/24, 9:59 AM